REGENXBIO Inc.
RGNX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $498,799 | $422,675 | $367,238 | $393,233 |
| - Cash | $58,802 | $79,558 | $130,104 | $57,526 |
| + Debt | $76,506 | $271,691 | $79,848 | $82,033 |
| Enterprise Value | $516,503 | $614,808 | $316,982 | $417,740 |
| Revenue | $29,733 | $21,359 | $89,012 | $21,214 |
| % Growth | 39.2% | -76% | 319.6% | – |
| Gross Profit | -$32,093 | $12,245 | $85,576 | $14,896 |
| % Margin | -107.9% | 57.3% | 96.1% | 70.2% |
| EBITDA | -$44,886 | -$55,973 | $18,608 | -$37,746 |
| % Margin | -151% | -262.1% | 20.9% | -177.9% |
| Net Income | -$61,941 | -$70,871 | $6,083 | -$51,186 |
| % Margin | -208.3% | -331.8% | 6.8% | -241.3% |
| EPS Diluted | -1.2 | -1.38 | 0.12 | -1.01 |
| % Growth | 13% | -1,250% | 111.9% | – |
| Operating Cash Flow | -$55,960 | -$49,342 | $33,629 | -$31,624 |
| Capital Expenditures | -$491 | -$391 | -$1,024 | -$1,079 |
| Free Cash Flow | -$56,451 | -$49,733 | $32,605 | -$32,703 |